Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 7,163 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87. Following the sale, the chief financial officer owned 284,321 shares of the company’s stock, valued at approximately $10,374,873.29. This represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.
- On Monday, May 18th, Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.64, for a total value of $187,938.00.
- On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.96, for a total value of $588,564.20.
- On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.90, for a total value of $956,279.80.
- On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.83, for a total transaction of $501,079.15.
Hims & Hers Health Stock Down 5.5%
Shares of Hims & Hers Health stock opened at $36.19 on Wednesday. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company has a market cap of $8.38 billion, a P/E ratio of -402.06, a PEG ratio of 107.73 and a beta of 2.35. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The firm has a fifty day moving average of $28.92 and a two-hundred day moving average of $26.33.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the company. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Barclays boosted their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 5th. JPMorgan Chase & Co. decreased their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Finally, Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $30.63.
Get Our Latest Stock Report on HIMS
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE increased its stake in Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after purchasing an additional 2,877,550 shares during the last quarter. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the last quarter. Norges Bank purchased a new stake in Hims & Hers Health in the 4th quarter valued at about $62,153,000. Invesco Ltd. increased its stake in shares of Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after acquiring an additional 1,600,004 shares during the last quarter. Finally, Clear Street Group Inc. acquired a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $87,372,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
